DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT03523585
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
Their cancer:
* cannot be removed by an operation
* has spread to other parts of the body
- Detailed Description
The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 608
-
Is the age of majority in their country
-
Has pathologically documented breast cancer that:
- is unresectable or metastatic
- has confirmed HER2-positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory
- was previously treated with ado-trastuzumab emtansine (T-DM1)
-
Has documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy)
-
Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh biopsy.
-
Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least:
- 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males)
- 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants)
- 7 months after the last dose of trastuzumab/capecitabine
-
Has adequate hematopoietic, renal and hepatic functions
- Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the adjuvant/neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy
- Has had prior treatment with capecitabine
- Has uncontrolled or significant cardiovascular disease
- Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Has active central nervous system (CNS) metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Trastuzumab deruxtecan (DS-8201a) Trastuzumab deruxtecan HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a Trastuzumab+capecitabine Capecitabine HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine Trastuzumab+capecitabine Trastuzumab HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine Lapatinib+capecitabine Capecitabine HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine Lapatinib+capecitabine Lapatinib HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine Baseline up to 46 months postdose Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine Baseline up to 46 months postdose The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine Baseline up to 46 months postdose Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine Baseline up to 46 months postdose Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine Up to 46 months Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.
Trial Locations
- Locations (224)
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
The Methodist Hospital Research Institute
🇺🇸Houston, Texas, United States
Az Groeninge
🇧🇪Kortrijk, Belgium
Sharp Memorial Hospital
🇺🇸San Diego, California, United States
Ospedale Sacro Cuore Don Calabria
🇮🇹Negrar, Verona, Italy
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
AMO - Assistência Multidisciplinar em Oncologia
🇧🇷Salvador, Bahia, Brazil
CliniOnco - Tratamento Integrado do Câncer
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Universitario Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Spain
Ironwood Cancer Research Centers
🇺🇸Chandler, Arizona, United States
UCLA Hematology Oncology - Main Site
🇺🇸Los Angeles, California, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Pacific Cancer Care
🇺🇸Monterey, California, United States
Florida Cancer Specialists-Broadway
🇺🇸Fort Myers, Florida, United States
Washington Cancer Institute
🇺🇸Washington, District of Columbia, United States
Piedmont Cancer Institute, PC
🇺🇸Atlanta, Georgia, United States
Kapiolani Medical Center for Women and Children/Univ of HI
🇺🇸Honolulu, Hawaii, United States
University of Maryland
🇺🇸Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
Cleveland Clinic Main Campus
🇺🇸Cleveland, Ohio, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
🇺🇸New York, New York, United States
The Ohio State University
🇺🇸Columbus, Ohio, United States
Abramson Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Allegheny General Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
UPMC Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
Macquarie University Hospital
🇦🇺Sydney, New South Wales, Australia
The Tweed Hospital
🇦🇺Tweed Heads, New South Wales, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Ashford Cancer Centre Research
🇦🇺Kurralta Park, South Australia, Australia
Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
Frankston Hospital
🇦🇺Frankston, Victoria, Australia
Calvary North Adelaide Hospital
🇦🇺Bruce, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
South West Oncology
🇦🇺Warrnambool, Victoria, Australia
Universitair Ziekenhuis Brussel
🇧🇪Bruxelles, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
CHU UCL Namur site de Sainte Elisabeth
🇧🇪Namur, Belgium
NOB - Núcleo de Oncologia da Bahia
🇧🇷Salvador, Bahia, Brazil
Pronutrir
🇧🇷Fortaleza, Ceará, Brazil
Oncobio Servicos de Saude
🇧🇷Nova Lima, Minas Gerais, Brazil
HGB - Hospital Giovanni Battista - Mãe de Deus Center
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Escosteguy Barrios, Carlos Henrique
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
🇧🇷Santo André, Sao Paulo, Brazil
Sociedade Beneficiente de Senhoras Hospital Sírio Libanês
🇧🇷São Paulo, Brazil
COI - Clínicas Oncológicas Integradas
🇧🇷Rio De Janeiro, Brazil
A. C. Camargo Cancer Center
🇧🇷São Paulo, Brazil
Hôpital Nord - CHU Marseille
🇫🇷Marseille cedex 20, Bouches-du-Rhône, France
CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
🇫🇷Plérin, Cotes d'Armor, France
Centre Georges François Leclerc
🇫🇷Dijon cedex, Côte-d'Or, France
CHU Brest - Hôpital Morvan
🇫🇷Brest Cedex, Finistere, France
Centre René Huguenin
🇫🇷Saint-Cloud, Hauts De Seine, France
Clinique Clementville
🇫🇷Montpellier, Herault, France
CRLCC Eugene Marquis
🇫🇷Rennes cedex, Ille Et Vilaine, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre Benite cedex, Rhone, France
Centre Hospitalier de la côte Basque
🇫🇷Bayonne Cedex, Pyrenees Atlantiques, France
Centre Henri Becquerel
🇫🇷Rouen, Seine Maritime, France
Hopital Tenon
🇫🇷Paris, France
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
🇩🇪Luebeck, Schleswig Holstein, Germany
Universitaetsklinikum Duesseldorf AoeR
🇩🇪Düsseldorf, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
Kliniken Koeln
🇩🇪Koeln, Germany
Klinikum der Universitaet Muenchen - Campus Grosshardern
🇩🇪Munich, Germany
Universitaetsklinikum Muenster
🇩🇪Müenster, Germany
General Oncology Hospital of Kifissia " Agioi Anargyroi"
🇬🇷Athens, Greece
University General Hospital of Heraklion
🇬🇷Heraklion, Greece
Euromedica General Clinic Thessaloniki
🇬🇷Thessaloníki, Greece
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
🇮🇹Monza, Milano, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
🇮🇹Bergamo, Italy
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
🇮🇹Bologna, Italy
Azienda Ospealiera della Provincia di Lecco
🇮🇹Lecco, Italy
Istituto Nazionale per la Ricerca sul Cancro di Genova
🇮🇹Genova, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
🇮🇹Messina, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
IEO Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Italy
A.O.U. Policlinico di Modena
🇮🇹Modena, Italy
IOV - Istituto Oncologico Veneto IRCCS
🇮🇹Padova, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
National Cancer Center Hospital
🇯🇵Chuo Ku, Tokyo-To, Japan
NHO Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Hyōgo College of Medicine Hospital
🇯🇵Hyōgo, Japan
St. Marianna University School of Medicine Hospital
🇯🇵Kanagawa, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Tohoku University Hospital
🇯🇵Miyagi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
NHO Osaka National Hospital
🇯🇵Osaka, Japan
Aichi Cancer Center Hospital
🇯🇵Nagoya, Japan
Saitama Cancer Center
🇯🇵Saitama, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Toranomon Hospital
🇯🇵Tokyo, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Inha University Hospital
🇰🇷Incheon, Gyeonggi-do, Korea, Republic of
The Catholic University of Korea, St. Vincent's Hospital
🇰🇷Suwon-si, Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Severance Hospital, Yonsei University
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
ICO Badalona - Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Hospital de Especialidades de Jerez de la Frontera
🇪🇸Jerez De La Frontera, Cádiz, Spain
Complejo Hospitalario Universitario A Coruña
🇪🇸A Coruña, La Coruña, Spain
Hospital Universitario de Canarias
🇪🇸San Cristobal de la Laguna, Tenerife, Spain
Hospital Infanta Cristina
🇪🇸Badajoz, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitari Arnau de Vilanova
🇪🇸Lleida, Spain
MD Anderson Cancer Centre
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Instituto Valenciano de Oncologia IVO
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Acibadem Adana Hospital
🇹🇷Adana, Turkey
Ankara Yildirim Beyazit Uni. Med. Fac.Ankara City Hospital
🇹🇷Ankara, Turkey
Uludag University Medical Faculty
🇹🇷Bursa, Turkey
Akdeniz University Medical Faculty
🇹🇷Antalya, Turkey
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital
🇹🇷Istanbul, Turkey
Medical Park Goztepe Hospital
🇹🇷Istanbul, Turkey
Medipol University Medical Faculty
🇹🇷Istanbul, Turkey
Kartal Lutfi Kirdar Research and Training Hospital
🇹🇷Istanbul, Turkey
Istanbul Medeniyet Uni Goztepe Training & Research Hospital
🇹🇷Istanbul, Turkey
Izmir Medicalpark Hospital
🇹🇷İzmir, Turkey
Konya Necmettin Erbakan University Meram Faculty of Medicine
🇹🇷Konya, Turkey
Medical Park Samsun Hastanesi
🇹🇷Samsun, Turkey
Sakarya Traning and Research Hospital
🇹🇷Sakarya, Turkey
Washington University
🇺🇸Saint Louis, Missouri, United States
Namik Kemal University
🇹🇷Tekirdağ, Turkey
Royal Cornwall Hospital
🇬🇧Truro, Cornwall, United Kingdom
Royal Devon and Exeter Hospital (Wonford)
🇬🇧Exeter, Devon, United Kingdom
Derriford Hospital
🇬🇧Plymouth, Devon, United Kingdom
Aberdeen Royal Infirmary
🇬🇧Aberdeen, Grampian Region, United Kingdom
Queen Mary University of London
🇬🇧London, Greater London, United Kingdom
Sarah Cannon Research Institute UK
🇬🇧London, Greater London, United Kingdom
University College London Hospitals
🇬🇧London, Greater London, United Kingdom
Western General Hospital
🇬🇧Edinburgh, Lothian Region, United Kingdom
Nottingham University Hospitals City Campus
🇬🇧Nottingham, Nottinghamshire, United Kingdom
Fakultni nemocnice Brno
🇨🇿Brno, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Nemocnice Na Bulovce
🇨🇿Praha, Czechia
North Shore Hematology Oncology Associates, PC
🇺🇸East Setauket, New York, United States
Community Hospital
🇺🇸Munster, Indiana, United States
Maine Center for Cancer Medicine
🇺🇸Scarborough, Maine, United States
Cornell-Beshore Cancer Institute
🇺🇸Joplin, Missouri, United States
Dayton Physicians, LLC
🇺🇸Kettering, Ohio, United States
Tennessee Oncology, PLLC Chattanooga
🇺🇸Chattanooga, Tennessee, United States
SCRI - Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
The West Clinic
🇺🇸Germantown, Tennessee, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
Community Cancer Trials of Utah
🇺🇸Ogden, Utah, United States
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
MultiCare Health System Institute for Research and Innovation
🇺🇸Tacoma, Washington, United States
Peninsula and South Eastern Haematology & Oncology Group
🇦🇺Frankston, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Sunshine Hospital
🇦🇺Saint Albans, Victoria, Australia
St John of God Subiaco Hospital
🇦🇺Subiaco, Western Australia, Australia
Ballarat Oncology & Haematology Service
🇦🇺Wendouree, Victoria, Australia
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Belgium
IBCC - Instituto Brasileiro de Controle do Câncer
🇧🇷São Paulo, Sao Paulo, Brazil
Fakultni nemocnice v Motole
🇨🇿Prague 5, Czechia
Centre François Baclesse
🇫🇷Caen Cedex 05, Calvados, France
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besançon, Doubs, France
Hôpital Privé d'Antony
🇫🇷Antony, Hauts De Seine, France
Institut Régional du Cancer de Montpellier
🇫🇷Montpellier, France
Centre de cancerologie les Dentellieres
🇫🇷Valenciennes, Nord, France
Institut Curie - site de Paris
🇫🇷Paris, France
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, Vaculuse, France
Institut Gustave Roussy
🇫🇷Villejuif cedex, Val De Marne, France
Klinikum rechts der Isar der TU Muenchen
🇩🇪Muenchen, Bayern, Germany
Universitaetsklinikum Leipzig AoeR
🇩🇪Leipzig, Germany
Helios-Kliniken Berlin-Buch
🇩🇪Berlin, Germany
Marienhospital Bottrop gGmbH
🇩🇪Bottrop, Rheinland Pfalz, Germany
251 General Air Force Hospital
🇬🇷Athens, Greece
Haematologisch-Onkologische Schwerpunktpraxis
🇩🇪Troisdorf, Germany
General Hospital of Athens "Alexandra"
🇬🇷Athens, Greece
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Rambam Health Care Center
🇮🇱Haifa, Israel
Sapir Medical Center, Meir Hospital
🇮🇱Kfar Saba, Israel
Rabin Medical Center-Beilinson Campus
🇮🇱Petah tikva, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
🇮🇹Cona, Italy
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Azienda Ospedaliero Universitaria di Parma
🇮🇹Parma, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino
🇮🇹Torino, Italy
Fukushima Medical University Hospital
🇯🇵Fukushima-shi, Fukushima-Ken, Japan
Kindai University Hospital
🇯🇵Ōsakasayama-shi, Osaka-Fu, Japan
NHO Shikoku Cancer Center
🇯🇵Ehime, Japan
NHO Hokkaido Cancer Center
🇯🇵Hokkaido, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
ICO l'Hospitalet - Hospital Duran i Reynals
🇪🇸L'Hospitalet De Llobregat, Barcelona, Spain
Hospital Quironsalud Barcelona
🇪🇸Barcelona, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinico Universitario Virgen de la Victoria
🇪🇸Málaga, Spain
Adana Numune Training and Research Hospital
🇹🇷Adana, Turkey
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
The University of Texas Health Science Center at Tyler
🇺🇸Tyler, Texas, United States
IRCCS Centro di Riferimento Oncologico
🇮🇹Aviano, Pordenone, Italy
Clinique Victor Hugo - Centre Jean Bernard
🇫🇷Le Mans Cedex 02, Sarthe, France
Loyola University Health System
🇺🇸Maywood, Illinois, United States
Centre Oscar Lambret
🇫🇷Lille cedex, Nord, France
Smilow Cancer Hospital at Yale New Haven
🇺🇸New Haven, Connecticut, United States
Saint Luke's Cancer Institute
🇺🇸Kansas City, Missouri, United States
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
🇺🇸Kansas City, Missouri, United States
Hospital Nossa Senhora da Conceição
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Clínica de Neoplasias Litoral Ltda.
🇧🇷Itajaí, Santa Catarina, Brazil
Related News
Current and future immunotherapy for breast cancer | springermedizin.de
- Prev
- 1
- Next